key: cord-0316935-7gl278ml
authors: Schwarz, T.; Otto, C.; Jones, T. C.; Pache, F.; Schindler, P.; Niederschweiberer, M.; Schmidt, F.; Drosten, C.; Corman, V. M.; Ruprecht, K.
title: A cohort of 222 anti-CD20 treated patients with multiple sclerosis followed through the COVID-19 pandemic: Attenuated humoral but robust cellular immune responses after vaccination and infection
date: 2021-10-19
journal: nan
DOI: 10.1101/2021.10.11.21264694
sha: 8d8f9d7c227db29fe42e9f73cbfe507a793ed920
doc_id: 316935
cord_uid: 7gl278ml

Importance: Data on immune responses following SARS-CoV-2 vaccinations/infections and on detection rate of SARS-CoV-2 infections in anti-CD20 treated patients with multiple sclerosis (pwMS) are important for guiding management of pwMS during the current SARS-CoV-2 pandemic. Objective: To analyze humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections and to determine the detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS. Design: Prospective single-center cohort study from March 2020 to August 2021. Setting: MS referral center, Charite - Universitaetsmedizin Berlin, Germany. Participants: 222 consecutive pwMS (128 [57.7%] female, median [range] age 39 [17-81] years). 181 patients were on anti-CD20 therapy at study inclusion, 41 began anti-CD20 therapy during the study. Hospital employees (HE, n=19) served as controls. Exposures: pwMS were exposed to anti-CD20 therapy for 169.5 patient years. 51 patients under anti-CD20 treatment, 14 patients before anti-CD20 treatment, and 19 HE were vaccinated twice against SARS-CoV-2. Main outcomes: SARS-CoV-2 spike protein immunoglobulin (Ig)G (ELISA and immunofluorescence), IgA (ELISA), IgG to four recombinant SARS-CoV-2 antigens (solid phase immunoassay), neutralizing capacity of SARS-CoV-2 antibodies (plaque reduction neutralization test), SARS-CoV-2 IgG avidity (modified ELISA), and SARS-CoV-2 specific T cells (interferon-{gamma} release assay). Results: Following two SARS-CoV-2 vaccinations, median (IQR) levels of SARS-CoV-2 spike protein IgG (OD ratio: 1.2 [0.1-5.1] vs. 9.0 [6.8-9.9] vs. 8.8 [8.0-9.4], p<0.0001), neutralizing capacity (PRNT50 Titer: 40 [0-80] vs. 640 [80-640] vs. 640 [320-640], p[≤]0.006), and antibody avidity (43.6% [14.8-54.6%] vs. 84.1% [53.1-86.8%] vs. 89.7 [76.8-93.4%], p[≤]0.003) were lower in anti-CD20 treated pwMS than in pwMS before initiation of anti-CD20 therapy and in HE. All anti-CD20 treated pwMS vaccinated twice developed SARS-CoV-2 specific T cells, whose levels did not differ from those of pwMS before initiation of anti-CD20 therapy and HE. SARS-CoV-2 IgG levels (r=0.42, p=0.002) and antibody avidity (r=0.70, p<0.001) increased with time between anti-CD20 infusion and second vaccination. The detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS (2.36/100 patient years) was similar to that of RT-PCR confirmed SARS-CoV-2 cases in the general Berlin population (3.75/100 person years) during the study period. Interpretation: These findings are relevant for treatment decisions as well as management of SARS-CoV-2 vaccinations in pwMS.

Management of immunotherapies and vaccinations against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are key issues in the clinical care of patients with multiple sclerosis (pwMS) during the current SARS-CoV-2 pandemic. 1, 2 Of particular concern, B-cell depleting anti-CD20 therapies have been associated with an increased risk of infections and decreased humoral immune responses to vaccinations. [1] [2] [3] [4] [5] [6] Indeed, serum levels of SARS-CoV-2 immunoglobulin (Ig)G following SARS-CoV-2 vaccinations and infections are reduced in anti-CD20 treated pwMS. [7] [8] [9] Nevertheless, in addition to antibody levels, protection from infection, and especially from severe courses of coronavirus disease-19 , may depend on neutralizing capacity and avidity of anti-SARS-CoV-2 antibodies as well as on induction of SARS-CoV-2 specific T cells. [10] [11] [12] However, data on anti-SARS-CoV-2 antibody neutralization capacity and avidity in anti-CD20 treated pwMS are scarce.

While very recent studies suggest that SARS-CoV-2 specific T cellular immune responses may be preserved in pwMS under anti-CD20 therapy, given the importance of these findings, independent confirmation appears warranted. 13, 14 The first laboratory-confirmed patient with COVID-19 in Germany was reported on January 27, 2020. 15 To monitor SARS-CoV-2 specific humoral immune responses in anti-CD20 treated pwMS, we started to prospectively collect sera for SARS-CoV-2 antibody determinations from pwMS treated with anti-CD20 therapies at the MS outpatient clinic, Charité Campus Mitte, Charité -Universitätsmedizin Berlin, Germany, on March 5, 2020. Following the start of the SARS-CoV-2 vaccination campaign in Germany in January 2021, we also assessed T cell responses to SARS-CoV-2 by interferon-γ release assays (IGRA). 16 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ;  https://doi.org/10.1101/2021. 10.11.21264694 doi: medRxiv preprint Here, we report results of detailed analyses of humoral and cellular immune responses following SARS-CoV-2 vaccinations/infections and the SARS-CoV-2 detection rate in a single-center cohort of 222 anti-CD20 treated pwMS followed through the first 17 months of the SARS-CoV-2 pandemic.

The study was approved by the ethical committee of Charité -Universitätsmedizin Berlin (EA2/152/21 and EA1/068/20).

Between March 5, 2020, and August 6, 2021 (herein referred to as study period), 222 consecutive pwMS, who were treated with at least one intravenous infusion of anti-CD20 therapy, were enrolled at the MS outpatient clinic, Charité Campus Mitte, Charité -Universitätsmedizin Berlin, Germany, in a prospective observational study.

Patients were either already treated with anti-CD20 therapy before March 5, 2020, or began anti-CD20 therapy during the study period. Details of the patients' treatments and the sampling scheme are described in the Supplement.

To detect anti-SARS-CoV-2 antibodies, a SARS-CoV-2 spike subunit 1 (S1) IgG and IgA ELISA Kit (Euroimmun, Lübeck, Germany) were used. 17 To confirm results obtained by ELISA, a recombinant anti-SARS-CoV-2 spike immunofluorescence test (IFT) 18 and a microarray-based multiparametric immunoassay for detection of IgG All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.11.21264694 doi: medRxiv preprint antibodies against spike and nucleocapsid protein (SeraSpot®Anti-SARS-CoV-2 IgG, Seramun Diagnostica GmbH, Heidesee, Germany) were applied. 17, 19 The neutralizing capacity of SARS-CoV-2 antibodies was analyzed by a plaque reduction neutralization test (PRNT), using authentic SARS-CoV-2. 18, 20 IgG avidity maturation was determined by a modified SARS-CoV-2 S1 ELISA (Euroimmun). 19 SARS-CoV-2 specific T cells were monitored utilizing a commercially available IGRA (Euroimmun). 19 Further details of the applied test systems and the applied statistical analyses are provided in the Supplement.

Between March 5, 2020, and August 6, 2021, 222 consecutive pwMS (177 with relapsing-remitting MS [RRMS] and 45 with primary progressive MS [PPMS]) were treated with at least one infusion of anti-CD20 therapy (220 with ocrelizumab and 2 with rituximab) at the MS outpatient clinic, Charité Campus Mitte, Charité -Universitätsmedizin Berlin, and included in this study. According to treatment status at the date of the latest sample collection, pwMS were grouped into those before initiation of anti-CD20 therapy (n=41) and those under anti-CD20 therapy (n=181).

Age, female/male ratio, the proportions of patients with RRMS/PPMS, the expanded disability status scale (EDSS) score, and the percentages of patients with any previous or at least two previous immunotherapies did not differ between pwMS before initiation of anti-CD20 therapy and under anti-CD20 therapy ( Table 1, for immunotherapies prior to anti-CD20 therapy see eTable 1). Nineteen hospital employees (HE), who were on average 7.5 years younger than pwMS, were included as controls ( Table 1) . All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. After the second SARS-CoV-2 vaccination, the frequency of patients with anti-SARS-CoV-2 S1 IgG antibodies above the assay threshold for reactivity was lower in anti-CD20 treated pwMS (26/51, 50.9%, 95%CI: 37.7-64.3%) than in pwMS before anti-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. compared to pwMS before anti-CD20 therapy (9.0 [6.8-9.9], p<0.0001) and to HE (8.8 [8.0-9.4 ], p<0.0001) (Figure 2A , eFigure 2B, eTable 2). No significant difference of anti-SARS-CoV-2 S1 IgG antibodies was detected between pwMS before anti-CD20 therapy and HE (p=1). Similar results were obtained for anti-SARS-2 S1 IgA antibodies (eFigure 2C). Likewise, anti-CD20 treated pwMS vaccinated twice had lower IgG levels against a recombinant SARS-CoV-2 full spike protein as All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ;  Impaired functionality of SARS-CoV-2 antibodies was also reflected in the maturation of IgG avidity: After two vaccinations, only 4/26 (15.4%, 95%CI: 6.2-33.5%) anti-CD20 treated pwMS had high anti-SARS-CoV-2 S1 IgG avidity indices compared to 10 Figure 2C , eFigure 2I). No differences were found in neutralizing capacity (p=0.74) and maturation of IgG avidity (p=0.36) in pwMS before anti-CD20 therapy and HE.

Cellular immune responses following two SARS-CoV-2 vaccinations were studied by an SARS-CoV-2 spike protein specific IGRA in all pwMS with a lithium heparinized blood sample available and in all HE. Remarkably, SARS-CoV-2 spike protein specific T cell responses were detectable in all anti-CD20 treated pwMS (26/26, 100%, 95%CI: 87.1-100%), similar to pwMS before anti-CD20 therapy (7/7, 100%, 95%CI: 64.6-100%, p=1), and HE (19/19, 100%, 95%CI: 83.2-100%, p=1, eTable 2).

Consequently, levels of IFN-γ released by SARS-CoV-2 spike protein specific T cells were similar between the three groups ( Figure 2D, eFigure 2J) .

Altogether, following two vaccinations against SARS-CoV-2, across all humoral immune response parameters, lower proportions of positive outcomes were detected in anti-CD20 treated pwMS than in pwMS before anti-CD20 therapy or in HE (Figure All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.11.21264694 doi: medRxiv preprint 2E, eTable 2). In contrast, SARS-CoV-2 specific T cells were detected in all twicevaccinated anti-CD20 treated pwMS, indicating the generation of a robust cellular immune response.

When analysing all 51 twice-vaccinated anti-CD20 treated pwMS, levels of anti-SARS-CoV-2 S1 IgG increased with increasing time between the last anti-CD20 therapy and the second vaccination (r=0.42, p=0.002, Figure 3A ). Of note, after an interval of >279 days between the last anti-CD20 therapy and the second vaccination, no anti-SARS-CoV-2 S1 IgG negative patients were detected.

Furthermore, in the 26 anti-SARS-CoV-2 S1 IgG antibody reactive anti-CD20 treated pwMS vaccinated twice, a strong positive correlation was observed between the relative avidity indices and the interval between the last anti-CD20 therapy and the second vaccination (r=0.70, p<0.001, Figure 3B ). Likewise, there was a positive correlation between the PRNT50 titer and the interval between the last anti-CD20 therapy and the second vaccination (r=0.44, p=0.03, Figure 3C ).

Anti-SARS-CoV-2 S1 IgG levels were not associated with age (r=-0.007, p=0.96, eFigure 3A) or time from the second vaccination to blood withdrawal (r=-0.05, p=0.75, eFigure 3B). Likewise, there was no association of relative avidity indices (r=0.18, p=0.46) or the PRNT50 titer (r=0.15, p=0.54) with the interval from the second vaccination to blood withdrawal (data not shown). Furthermore, no associations were observed between anti-SARS-CoV-2 S1 IgG antibody levels and All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ;  total serum IgG levels (r=0.18, p=0.25, eFigure 3C) or the cumulative lifetime dose of anti-CD20 therapy (r=0.04, p=0.78, eFigure 3D) .

Levels of SARS-CoV-2 S1 specific T cell responses did not correlate with the level of anti-SARS-CoV-2 S1 IgG antibodies (r=-0.21, p=0.31, eFigure 3E) or the interval between last anti-CD20 treatment and the second SARS-CoV-2 vaccination (r=-0.31, p=0.13, eFigure 3F) Five of 9 patients were infected with SARS-CoV-2 before initiation of anti-CD20 therapy. In these 5 patients, symptoms of SARS-CoV-2 infection were overall mild to moderate and none of the patients needed hospitalization (eTable 3). Of note, 3 of All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.11.21264694 doi: medRxiv preprint these 5 patients were first diagnosed with MS after SARS-CoV-2 infection. Four of 9

patients were under anti-CD20 therapy at the time they had symptoms compatible with COVID-19. While symptoms were mostly mild to moderate, one of these patients had a more severe course, including worsening of pre-existing MS symptoms requiring hospitalization but no intensive care treatment (eTable 4).

Altogether, none of the 9 patients died of COVID-19 and all 9 recovered fully.

For each patient, observation time was defined as the interval between March 5, 2020 and the date of the latest sample collection. The total observation time of anti-CD20 treated pwMS was 169.5 patients years. The total observation time for patients before initiation of anti-CD20 therapy, that is, anti-CD20 therapy-naïve patients, was 51.6 patient years. The detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS was 2.36/100 patient years. In anti-CD20 therapy-naïve pwMS, it was 9.69/100 patient years. The detection rate of RT-PCR confirmed SARS-CoV-2 cases in the total population of Berlin during the study period was 3.75/100 person years. 21

The key findings of this comprehensive analysis of SARS-CoV-2 specific humoral and cellular immune response in a large cohort of pwMS monitored throughout 17 months of the SARS-CoV-2 pandemic are (1) that levels and functionality of antibody responses to SARS-CoV-2 vaccinations were diminished in anti-CD20 treated patients with MS, but this was attenuated with increasing time from the last anti-CD20 infusion to the second vaccination; (2) that pwMS under anti-CD20 therapy developed robust T cell responses following SARS-CoV-2 vaccinations/infections; All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.11.21264694 doi: medRxiv preprint and (3) that the detection rate of SARS-CoV-2 infections in anti-CD20-treated pwMS was similar to that of the general population.

Our current findings extend previous work showing diminished humoral immune responses to SARS-CoV-2 vaccinations in anti-CD20 treated pwMS 8,13,14,22 by demonstrating that not only antibody levels, but also the functionality of SARS-CoV-2 antibodies is reduced in anti-CD20 treated pwMS. Of note, the diminished avidity of SARS-CoV-2 antibodies suggests that B cell depletion by anti-CD20 therapies interferes with normal antibody maturation, which appears relevant also for other vaccinations in patients treated with anti-CD20 therapies. 23 Importantly, SARS-CoV-2 antibody levels, avidity and neutralizing capacity increased with increasing time from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination in anti-CD20 treated pwMS. This is most likely explained by increasing numbers of reappearing B cells with increasing time after anti-CD20 infusion. Indeed the interval from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination of >279 days after which no negative SARS-CoV-2 IgG patients were identified is consistent with slow B cell repopulation starting about 6 months after the last anti-CD20 infusion. 24 From a clinical perspective, our data suggest that to enhance humoral immune responses, SARS-CoV-2 vaccinations should be applied as late as possible within the 6 monthly infusion cycles of intravenous anti-CD20 therapy. Furthermore, if clinically justified, one may consider prolonging the infusion interval between anti-CD20 infusions to increase chances of successful SARS-CoV-2 vaccinations. 25 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.11.21264694 doi: medRxiv preprint memory. 11, 12, 28 Easily assessable correlates of protection, such as antibody or T cell cut-off values, have therefore not been and will possibly not be identified. To analyse the clinical significance of reduced antibody levels, but preserved T cell responses against SARS-CoV-2, longitudinal studies of SARS-CoV-2 breakthrough infections in anti-CD20 treated pwMS vaccinated against SARS-CoV-2 will be required.

Whereas the detection rate of SARS-CoV-2 infected anti-CD20 treated pwMS was similar to that of the total population of Berlin, we cannot exclude that the number of SARS-CoV-2 infections in anti-CD20 treated pwMS is an underestimate, as detection of infections was mainly based on detection of SARS-CoV-2 antibodies, which may be undetectable under anti-CD20 therapy. 29 However, all three SARS-CoV-2 RT-PCR positive patients also had detectable anti-SARS-CoV-2 antibodies, indicating that anti-SARS-CoV-2 specific antibodies can be generated in anti-CD20 treated pwMS upon SARS-CoV-2 infection. Interestingly, the detection rate of SARS-CoV-2 infections was lower in anti-CD20 treated pwMS than in pwMS before initiation of anti-CD20 therapy. One explanation for this finding might be a possible change in behaviour of pwMS receiving anti-CD20 therapy, such as stricter mask wearing and avoidance of potentially risky situations.

Limitations of this observational study include lack of data on total lymphocyte and B cell counts at the time of SARS-CoV-2 vaccinations/infections precluding evaluations of these parameters as potential risk factors for low vaccine immunogenicity.

Furthermore, given the limited follow-up time of the present study and potentially decreasing SARS-CoV-2 immune responses over time, it will be important to analyse All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ; https://doi.org/10.1101/2021.10.11.21264694 doi: medRxiv preprint

(A) Sera of anti-CD20 treated pwMS (anti-CD20), pwMS before anti-CD20 therapy (no anti-CD20) and HE were tested for SARS-CoV-2 specific S1 IgG antibodies. SARS-CoV-2 specific S1 IgG OD ratios among pwMS after two vaccinations, pwMS who were not vaccinated/infected, and pwMS after SARS-CoV-2 infections are shown. The dotted horizontal line represents an OD ratio of 1.1, levels above which indicate the presence of anti-SARS-CoV-2 S1 IgG. (B) Functionality of SARS-CoV-2 specific antibodies after two vaccinations was analysed in anti-CD20 treated pwMS, pwMS before anti-CD20 therapy, and HE by determination of neutralizing antibodies using a plaque reduction neutralization test (PRNT) and (C) IgG avidity maturation. Dotted horizontal lines indicate relative antibody indices >40%, which were considered borderline, and relative antibody indices >60% which were considered high avidity. (D) SARS-CoV-2 specific T cell responses were measured in whole blood samples by IGRA in pwMS and HE vaccinated twice and in pwMS who were not vaccinated/infected. SARS-CoV-2 specific T cells were considered to be present if IFN-γ release was higher than the highest value in the not vaccinated/infected control group (111.41 mIU/ml, dotted horizontal line). (E) Heatmap summarizing the percentage of positive outcomes per test in pwMS and HE (results for groups with n<3 were not included). Horizontal lines indicate the median. P values were calculated by the non-parametric Kruskal-Wallis test with Dunn's multiple comparisons test.

HE: hospital employees, vac: vaccination, S1: SARS-CoV-2 spike protein S1 domain, IgG: immunoglobulin G, IgA: immunoglobulin A, OD: optical density, IFT: immunofluorescence test, PRNT: plaque reduction neutralization test, IGRA: interferon-γ release assay, IFN-γ: interferon γ , IU: international units, ns: not significant

(A) Correlation of anti-SARS-CoV-2 S1 IgG OD ratio and interval from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination in anti-CD20 treated pwMS (n=51). (B) Correlation of relative avidity index and (C) PRNT50 titer with the interval from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination in anti-SARS-CoV-2 S1 IgG reactive anti-CD20 treated pwMS (n=26). Correlations were calculated by Spearman's method. S1: SARS-CoV-2 spike protein S1 domain, IgG: immunoglobulin G, OD: optical density, PRNT: plaque reduction neutralization test, d: days In pairwise comparison with Mann-Whitney-U tests, age did not differ between patients with MS (pwMS) under anti-CD20 therapy and pwMS before anti-CD20 therapy (p=0.08), as well as between pwMS before anti-CD20 therapy and hospital employees (HE, p=0.09), but HE were younger than pwMS under anti-CD20 therapy (p=0.0014) c Details of previous treatments are listed in eTable 1 d Cumulative lifetime dose of anti-CD20 therapy per patient until August 6, 2021 e One patient had previously been treated with a cumulative lifetime dose of 8000 mg rituximab followed by an anti-CD20 treatment free interval of >18 months before anti-CD20 therapy was re-initiated with ocrelizumab during the course of this study EDSS: Expanded Disability Status Scale, MS: multiple sclerosis, n: number, RRMS: relapsing remitting multiple sclerosis, PPMS: primary progressive multiple sclerosis All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 19, 2021. ;  222 patients with multiple sclerosis, 397 blood samples collected between 5 March 2020 and 6 August 2021 

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy

Demory Beckler M. Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies

COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. The Lancet Rheumatology

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with highefficacy disease-modifying therapies

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Adaptive immunity to SARS-CoV-2 and COVID-19

CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly

Virological assessment of hospitalized patients with COVID-2019

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv

Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2

Correlates of protection against SARS-CoV-2 in rhesus macaques

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

We thank Betina Jaenicke, Anita Kaiser-Friedrich, Marie Luisa Schmidt, Patricia